CN115645473A - Application of arundina graminifolia and extract thereof in preparation of medicine for treating kidney injury - Google Patents
Application of arundina graminifolia and extract thereof in preparation of medicine for treating kidney injury Download PDFInfo
- Publication number
- CN115645473A CN115645473A CN202211418261.6A CN202211418261A CN115645473A CN 115645473 A CN115645473 A CN 115645473A CN 202211418261 A CN202211418261 A CN 202211418261A CN 115645473 A CN115645473 A CN 115645473A
- Authority
- CN
- China
- Prior art keywords
- extract
- arundina graminifolia
- kidney injury
- arundina
- graminifolia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001313869 Arundina graminifolia Species 0.000 title claims abstract description 44
- 239000000284 extract Substances 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 206010061481 Renal injury Diseases 0.000 title claims abstract description 24
- 208000037806 kidney injury Diseases 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 5
- 238000000605 extraction Methods 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 208000009304 Acute Kidney Injury Diseases 0.000 claims abstract description 10
- 208000033626 Renal failure acute Diseases 0.000 claims abstract description 10
- 201000011040 acute kidney failure Diseases 0.000 claims abstract description 10
- 230000001684 chronic effect Effects 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 229930024421 Adenine Natural products 0.000 claims description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 6
- 229960000643 adenine Drugs 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 241000700159 Rattus Species 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000001681 protective effect Effects 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 15
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000000465 moulding Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- -1 ACEI Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000745390 Lophatherum Species 0.000 description 1
- 208000032028 Microvascular Rarefaction Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides application of arundina graminifolia and an extract thereof in preparing a medicament for treating kidney injury and discloses an extraction method of the arundina graminifolia extract. The invention firstly shows that the arundina graminifolia and the extract thereof have obvious protective effect on the models of acute kidney injury of mice and chronic kidney injury of rats through biological kidney injury model experiments, provides new application for the traditional Chinese medicine arundina graminifolia, and simultaneously provides new thought for the research and development of novel anti-kidney injury medicines.
Description
Technical Field
The invention relates to an application of arundina graminifolia and an extract thereof, in particular to an application in preparing a medicine for treating renal injury.
Background
The kidney is a complex biological system with a wide variety of regulatory mechanisms and physiological functions, and kidney disease: improvement of clinical practice guidelines for global clinics indicates that when renal function is impaired or gradually declines, renal excretion and regulation efficacy will also be reduced, and when renal function is severely impaired, uremia will occur, endangering life. Epidemiological studies have shown that about 15% of adults and 25% of hospitalized children suffer from acute kidney injury, while the incidence of acute kidney injury is even higher in patients undergoing intensive care (> 57% in a large international study). Many studies have shown that acute kidney injury can increase the risk of chronic kidney disease, leading to fibrosis, vascular rarefaction, tubular loss, glomerulosclerosis and chronic inflammation after the acute phase of injury, which may gradually become chronic renal failure if not treated in time, and seriously affect the quality of life of people. Despite decades of intensive research, the complex pathogenesis of renal injury remains unexplained.
At present, no effective treatment means exists clinically for kidney injury, the target drugs hardly play a synergistic effect, and clinically mainstream drugs such as hormones, antibiotics and antihypertensive drugs need to be used for a long time and need higher concentration. However, high dose and high concentration of the drug also bring about serious adverse reactions, such as non-steroidal anti-inflammatory drugs (NSAIDs), hormone drugs, penicillin antibiotics, ACEI, immunosuppressive drugs and the like, which often cause serious side effects, so that the drug has important significance in improving the safety and effectiveness of the drug for treating kidney diseases.
Herba Arundinis Purpureae (D.Don) Hochr.) belonging to family Orchidaceae, genus Lophatherum, is a common medicine for Dai family, and can be used for treating food poisoning. As traditional detoxifying traditional Chinese medicine, the application of arundina graminifolia and extracts thereof in other new fields is discovered in succession, for example, chinese patent with publication number CN107050301B applies the extract to inhibiting the increment of salmonella; the Chinese patent with the publication number CN105326890A is applied to the preparation of the medicine for treating gastric ulcer. The inventor of the invention finds that the arundina graminifolia and the extract thereof have good kidney injury resistance in the process of screening the drug activity, but the record of the application of the arundina graminifolia in the kidney injury resistance is not searched in the prior art, and the application of the arundina graminifolia and the extract thereof is helpful for providing a thought for novel kidney injury resistance drugs.
Disclosure of Invention
According to the background technology, the invention provides the application of arundina graminifolia and the extract thereof in preparing the medicine for resisting renal injury.
In the application, the arundina graminifolia extract is an aqueous extract or an alcohol extract of arundina graminifolia.
In the application, the extraction method of the arundina graminifolia extract comprises the following steps:
the method comprises the following steps: weighing 1 part of arundina graminifolia, adding 5-20 parts of an extraction solvent, and filtering to obtain an extracting solution;
step two: and (3) carrying out suction filtration on the extracting solution obtained in the step one, concentrating and drying to obtain the arundina graminifolia extract.
In the application, the extraction solvent is methanol, the extraction times are 2-3 times, and each time of extraction lasts for 0.5-2h.
In the application, the extraction mode of the extracting solution in the step one is ultrasonic extraction, and the extraction temperature is 40-60 ℃.
In the application, the concentration in the second step is rotary evaporation concentration, and the rotary evaporation temperature is 50 ℃.
In the above application, the drying in the second step is drying, decompression or freeze-drying.
In the application, the arundina graminifolia or the arundina graminifolia extract is 0.1-1g of crude drug per kilogram of body weight (human).
In the above use, the kidney injury is acute kidney injury caused by cisplatin or chronic kidney injury caused by adenine.
In the application, the dosage form of the medicine is tablets, granules or oral preparations.
In the process of screening the drug activity, the inventor of the invention proves that the arundina graminifolia and the extract thereof can inhibit the kidney inflammatory factor and effectively protect acute kidney injury caused by cis-platinum and chronic kidney injury caused by adenine through pharmacological experiments, provides a new application for the traditional Chinese medicine arundina graminifolia, and simultaneously provides a new thought for a novel anti-kidney injury drug. In addition, the method for extracting the arundina graminifolia provided in the embodiment is simple in process, low in extraction difficulty and easy to popularize and apply to the kidney injury resistant medicine.
Drawings
FIG. 1 is an HE staining light microscope image of kidney tissues of mice in blank group, model group, high/medium/low dose group, respectively, in example 2 of the present invention; wherein # p <0.01 compared to blank group, # p <0.001, # p <0.01, and # p <0.05 compared to model group.
Detailed Description
The invention is further described below with reference to the following figures and specific examples.
Example 1: preparing the arundina graminifolia extract.
The extraction method of the arundina graminifolia extract comprises the following steps:
the method comprises the following steps: weighing 1 part of arundina graminifolia, adding 5-20 parts of methanol, refluxing, ultrasonically treating or leaching for multiple times, filtering, and mixing to obtain an extracting solution. In the embodiment, ultrasonic extraction is carried out in water bath for 2-3 times at 40-60 deg.C, wherein the effective dose for resisting nephritis is herba Arundinis Purpureae or its extract with a raw drug amount of 0.1-1g per kg body weight (human).
Step two: and (3) carrying out suction filtration on the extracting solution obtained in the step one, carrying out rotary evaporation and concentration at 50 ℃ until the phenomenon of wall hanging stops, and drying, decompressing or freeze-drying the filtrate to obtain the arundina graminifolia extract. Taking out and weighing, and calculating the extraction rate.
Example 2: the bamboo leaf orchid extract is used for performing pharmacodynamic activity experiments on acute kidney injury caused by cisplatin.
a. The molding and administration method comprises the following steps:
50 KM mice are selected and divided into a blank group, a model group and a high/medium/low dose group, wherein the blank group is not subjected to molding treatment, and the groups except the blank group are prepared into 1mg/mL cis-platinum concentration by pure water and are subjected to single intraperitoneal injection molding according to the dose of 10 mg/kg. The high, medium and low dose groups are administrated by using the arundina graminifolia extract prepared in the example 1, the dosage is respectively reduced to 6/3/1.5g of crude drug of the arundina graminifolia per kilogram of body weight (mouse) per day, the injection is carried out after the administration for 14 days by pre-gastric perfusion, the administration is continued for 3 days, the eyeball blood collection is started after the administration for 2 hours on the 3 rd day, the kidney is taken for preservation, and the slicing process is as follows:
the kidney tissue was fixed with 4% neutral formaldehyde solution and stored at 4 ℃ for 12 hours. After fixation, kidney tissue was removed, rinsed with running water for 1 hour, and dehydrated as follows: 75% ethanol, 1 hour; 85% ethanol, 1 hour; 95% ethanol for 1 hour; 95% ethanol for 3 hours; absolute ethyl alcohol for 0.5 hour; absolute ethyl alcohol for 2 hours; xylene I,1 hour; xylene II, permeabilization for 1 hour; standing the paraffin I for 1 hour; paraffin II was allowed to stand for 3 hours. Then embedding paraffin, slicing 3-4 microns, baking the slices at 60 ℃ for 5 hours, dewaxing the xylene for five times, 5 minutes each time, and then placing the absolute ethyl alcohol I for 5 minutes; placing the absolute ethyl alcohol II for 5 minutes; standing for 5 minutes by using 95% ethanol I; standing the mixture with 95% ethanol II for 5 minutes; standing 80% ethanol for 5 min; standing with 70% ethanol for 5 min; flushing for 5 minutes by running water; the hematoxylin fuel is placed for 5 minutes; color separation is carried out for 5 seconds by 0.5 percent hydrochloric acid alcohol; washing with water and bluing for 20 minutes; standing with 70% ethanol for 5 min; standing 80% ethanol for 5 min; the eosin dye solution is placed for 20 seconds; standing for 5 minutes by using 95% ethanol I; standing the mixture with 95% ethanol II for 5 minutes; placing the solution of the xylene and the ethanol 1:1 for 5 minutes; placing the xylene I for 5 minutes; placing the xylene II for 5 minutes; placing the xylene III for 5 minutes; after staining was completed, the gel was air-dried, and then the gel was mounted on neutral resin, and the histopathological changes of the kidney were observed under a microscope.
b. The implementation results are as follows:
the experimental results are shown in A-D in FIG. 1, FIG. 1A is kidney sample retention comparison of 5 groups of mice, and the kidney tissue morphology of the blank group of mice is normal; the renal tubular epithelial cells of the mice in the model group are subjected to edema and necrosis, the renal interstitium is infiltrated by inflammatory cells, and the shape of the renal glomerulus is approximately normal; the tubular necrosis degree of the arundina graminifolia high/medium/low dose group was significantly reduced compared to the model group, and the glomerulus was approximately normal.
Fig. 1B-D show organ index, urea nitrogen, and blood creatinine of 5 groups of mice, respectively, and the results show that the arundina graminifolia high/medium/low dose groups can effectively reduce the kidney organ index of mice caused by cisplatin, reduce the urea nitrogen and blood creatinine content in the model group, and indicate that the arundina graminifolia extract has a certain protective effect on acute kidney injury of mice caused by cisplatin.
Example 3: the pharmacodynamic activity test of the arundina graminifolia extract on the chronic kidney injury caused by adenine.
a. The molding and administration method comprises the following steps:
60 SD rats are selected and divided into a blank group, a model group, a high/medium/low dose group and a positive drug group, wherein the blank group is not subjected to modeling treatment, except 10 blank groups, the rest groups are prepared into suspension by adenine according to the dose of (300 mg/kg/d) and distilled water, the suspension is perfused into the stomach at fixed time every day for 4 weeks, and the chronic kidney injury model of the rats can be formed by freely drinking water and eating.
After molding, the high/medium/low dose groups of arundina graminifolia were dispensed in an amount of 3/2/1 g/kg body weight (rat) per day. The administration was started one day after the molding and continued for 28 days. The blank and model groups are intragastrically filled with a solvent, the arundina graminifolia medicament group is intragastrically filled with the arundina graminifolia extract in the example 1, and the positive medicament group is intragastrically filled with losartan.
b. The experimental results are as follows:
the organ indexes of each group are compared as follows:
# p <0.01 compared to blank; p <0.01, p <0.05 compared to model group.
Creatinine and urea nitrogen content for each group were compared as follows:
# p <0.01 compared to blank; p <0.01, p <0.05 compared to model group.
The contents of TNF-alpha, IL-1 beta and IL-6 in each group are compared as follows:
# p <0.01 compared to blank; p <0.01, p <0.05 compared to model group.
The results show that the arundina graminifolia extract can effectively inhibit the kidney inflammatory factor and protect the chronic kidney injury caused by adenine or the acute kidney injury caused by cisplatin.
While the preferred embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that the invention is not limited to the embodiments disclosed, but is capable of various modifications and substitutions without departing from the spirit of the invention.
Claims (10)
1. Application of arundina graminifolia and extract thereof in preparing medicine for treating renal injury is provided.
2. The use of claim 1, wherein: the arundina graminifolia extract is an aqueous extract or an alcohol extract of arundina graminifolia.
3. Use according to claim 2, characterized in that: the extraction method of the arundina graminifolia extract comprises the following steps:
the method comprises the following steps: weighing 1 part of arundina graminifolia, adding 5-20 parts of an extraction solvent, and filtering to obtain an extracting solution;
step two: and (3) carrying out suction filtration on the extracting solution obtained in the step one, concentrating and drying to obtain the arundina graminifolia extract.
4. Use according to claim 3, characterized in that: the extraction solvent is methanol, the extraction times are 2-3 times, and each time of extraction is 0.5-2h.
5. The use of claim 4, wherein: the extraction mode of the extracting solution in the first step is ultrasonic extraction, and the extraction temperature is 40-60 ℃.
6. The use of claim 4, wherein: and in the second step, the concentration is rotary evaporation concentration, and the rotary evaporation temperature is 50 ℃.
7. The use of claim 4, wherein: and drying, decompressing or freeze-drying in the step two.
8. Use according to claim 2, characterized in that: the dosage of the arundina graminifolia or the arundina graminifolia extract which is taken by a person is 0.1-1g of crude drug per kilogram of body weight.
9. The use of claim 8, wherein: the kidney injury is acute kidney injury caused by cisplatin or chronic kidney injury caused by adenine.
10. Use according to claim 2, characterized in that: the dosage form of the medicine is tablets, granules or oral preparations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211418261.6A CN115645473A (en) | 2022-11-14 | 2022-11-14 | Application of arundina graminifolia and extract thereof in preparation of medicine for treating kidney injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211418261.6A CN115645473A (en) | 2022-11-14 | 2022-11-14 | Application of arundina graminifolia and extract thereof in preparation of medicine for treating kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115645473A true CN115645473A (en) | 2023-01-31 |
Family
ID=85021586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211418261.6A Pending CN115645473A (en) | 2022-11-14 | 2022-11-14 | Application of arundina graminifolia and extract thereof in preparation of medicine for treating kidney injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115645473A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117653580A (en) * | 2023-11-16 | 2024-03-08 | 广东省农业科学院环境园艺研究所 | Herba Lophatheri extract, and its preparation method and application in cosmetics |
-
2022
- 2022-11-14 CN CN202211418261.6A patent/CN115645473A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117653580A (en) * | 2023-11-16 | 2024-03-08 | 广东省农业科学院环境园艺研究所 | Herba Lophatheri extract, and its preparation method and application in cosmetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105582000A (en) | Preparation method of terpenoid and lignan substances in eucommia ulmoides bark or eucommia ulmoides leaves and application of terpenoid and lignan substances in preparation of senile dementia treatment drug | |
| CN102702582A (en) | Zeamays L. polysaccharide and preparation method and application thereof | |
| CN115645473A (en) | Application of arundina graminifolia and extract thereof in preparation of medicine for treating kidney injury | |
| CN104435034B (en) | A kind of arasaponin and preparation method thereof | |
| CN102488806A (en) | Renal failure treating Chinese medicinal preparation and preparation method thereof | |
| JP2002538214A (en) | Pharmaceutical composition for treating cardiovascular disease and method for producing the same | |
| CN114292346B (en) | Poria cocos total polysaccharide and extraction method and application thereof | |
| CN103405501B (en) | Preparation method of three-component blood-activating and stasis-dissolving capsules | |
| CN107041924A (en) | It is a kind of prevent and treat diabetic nephropathy towards medicine compound extract and preparation method thereof | |
| CN101444599B (en) | Corn silk extract and preparation method thereof and application thereof in preparing drugs for treating gout | |
| CN114404462B (en) | Composition and application thereof in preparation of medicine for treating gastric injury and/or gastric ulcer | |
| CN102038913A (en) | Oral preparation for treating cerebral apoplexy and preparation method and application thereof | |
| TWI438001B (en) | Plant extract for treating diabetes and process for making same | |
| WO2008091064A1 (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| CN111419999B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN1907432A (en) | Application of polysaccharide from the Gastrodia elata Blume in health caring stuff and medicine | |
| CN112603978A (en) | Traditional Chinese medicine composition for treating type 2 diabetes combined with coronary heart disease and preparation method thereof | |
| CN111544473A (en) | Refined coronary heart disease granule extraction preparation process for treating coronary heart disease and angina pectoris, traditional Chinese medicine and extract thereof | |
| WO2021128232A1 (en) | Ophiopogonis radix degradation extract and use thereof in preparation of hypoglycemic drugs | |
| CN115671219B (en) | Traditional Chinese medicine composition for treating gout and preparation method and application thereof | |
| CN114767760B (en) | A composition with liver protecting effect | |
| CN100486610C (en) | Shenkeshu capsule for treating chronic renal failure and its preparation technology | |
| CN115887513B (en) | Application of extract of leaf of petaled sea Sang Nenzhi in preparation of hyperuricemia medicament | |
| CN108743654B (en) | Traditional Chinese medicine composition for treating ischemic heart disease and preparation method and application thereof | |
| CN111450144B (en) | Application of ficus microcarpa leaf extract in preparation of medicines for preventing and/or treating diabetes and complications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |